Literature DB >> 10765076

Percentage of cancer on biopsy cores accurately predicts extracapsular extension and biochemical relapse after radical prostatectomy for T1-T2 prostate cancer.

V Ravery1, C Chastang, M Toublanc, L Boccon-Gibod, V Delmas, L Boccon-Gibod.   

Abstract

PURPOSE: To perform a multivariate analysis to investigate the usefulness of eight preoperative variables as predictors of final pathological stage (pT), positive surgical margins (PSM) and biological progression after radical prostatectomy (RP).
MATERIALS AND METHODS: In 143 patients undergoing RP for T1-T2 prostate cancer, the respective values of age, clinical stage, preoperative prostate-specific antigen (PSA), prostate-specific antigen density (PSAD), number of positive biopsies (NPB), Gleason score, length of tissue core invaded by cancer (LTI) and topography (uni/bilaterality) of positive biopsies for predicting extracapsular extension, PSM and biochemical failure (PSA> or =0.05 ng/ml) were evaluated retrospectively. Univariate and multivariate analyses were applied to define the statistical significance of each variable. Actuarial survival without biological progression was calculated using the Kaplan-Meier method (log-rank test).
RESULTS: In this series, 44.8% of patients had extracapsular extension with 41.3% PSM. The mean PSA was 12.4 ng/ml. In univariate analysis, LTI (p<0.0001), NPB (p = 0.0023), PSA (p = 0.0039) and Gleason score (p = 0.0136) were the most powerful variables to predict pT stage; however, in logistic regression analysis, LTI was the most predictive feature. For prediction of PSM, some variables (LTI, NPB and PSA) were found to be of statistical value in univariate analysis, and LTI in combination with NPB and PSA in multivariate analysis. For biological progression, statistical analysis (log rank test) showed PSAD and LTI to be significant predictors.
CONCLUSION: The pathological report regarding the biopsy contains crucial information influencing the prediction of pT stage, PSM and biological progression after RP. LTI, NPB and PSA are the most useful parameters for this purpose.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10765076     DOI: 10.1159/000020167

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  10 in total

1.  The value of PSA, free-to-total PSA ratio and PSA density in the prediction of pathologic stage for clinically localized prostate cancer.

Authors:  Güven Aslan; Bora Irer; Aykut Kefi; Ilhan Celebi; Kutsal Yörükoğlu; Adil Esen
Journal:  Int Urol Nephrol       Date:  2005       Impact factor: 2.370

Review 2.  Imaging and evaluation of patients with high-risk prostate cancer.

Authors:  Marc A Bjurlin; Andrew B Rosenkrantz; Luis S Beltran; Roy A Raad; Samir S Taneja
Journal:  Nat Rev Urol       Date:  2015-10-20       Impact factor: 14.432

3.  Significance of the percentage of prostate needle biopsy cores with cancer as a predictor of disease extension in radical prostatectomy specimens in Japanese men.

Authors:  Iori Sakai; Ken-ichi Harada; Isao Hara; Hiroshi Eto; Hideaki Miyake
Journal:  Int Urol Nephrol       Date:  2005       Impact factor: 2.370

4.  Magnetic Resonance Imaging/Transrectal Ultrasonography Fusion Prostate Biopsy Significantly Outperforms Systematic 12-Core Biopsy for Prediction of Total Magnetic Resonance Imaging Tumor Volume in Active Surveillance Patients.

Authors:  Chinonyerem Okoro; Arvin K George; M Minhaj Siddiqui; Soroush Rais-Bahrami; Annerleim Walton-Diaz; Nabeel A Shakir; Jason T Rothwax; Dima Raskolnikov; Lambros Stamatakis; Daniel Su; Baris Turkbey; Peter L Choyke; Maria J Merino; Howard L Parnes; Bradford J Wood; Peter A Pinto
Journal:  J Endourol       Date:  2015-07-23       Impact factor: 2.942

5.  Measurements of cancer extent in a conservatively treated prostate cancer biopsy cohort.

Authors:  Ramzi Rajab; Gabrielle Fisher; Michael W Kattan; Christopher S Foster; Tim Oliver; Henrik Møller; Victor Reuter; Peter Scardino; Jack Cuzick; Daniel M Berney
Journal:  Virchows Arch       Date:  2010-09-09       Impact factor: 4.064

Review 6.  Saturation biopsies for prostate cancer: current uses and future prospects.

Authors:  Nicolas B Delongchamps; Gabriel P Haas
Journal:  Nat Rev Urol       Date:  2009-11-10       Impact factor: 14.432

7.  Diagnostic accuracy of extended biopsies for the staging of microfocal prostate cancers in autopsy specimen.

Authors:  N B Delongchamps; G de la Roza; V Chandan; R Jones; G Threatte; M Jumbelic; G P Haas
Journal:  Prostate Cancer Prostatic Dis       Date:  2008-07-15       Impact factor: 5.554

8.  Variation in reporting of cancer extent and benign histology in prostate biopsies among European pathologists.

Authors:  D M Berney; F Algaba; P Camparo; E Compérat; D Griffiths; G Kristiansen; A Lopez-Beltran; R Montironi; M Varma; L Egevad
Journal:  Virchows Arch       Date:  2014-03-04       Impact factor: 4.064

Review 9.  Prognostic histopathological and molecular markers on prostate cancer needle-biopsies: a review.

Authors:  A Marije Hoogland; Charlotte F Kweldam; Geert J L H van Leenders
Journal:  Biomed Res Int       Date:  2014-08-27       Impact factor: 3.411

10.  (68)Ga-HBED-CC-PSMA PET/CT Versus Histopathology in Primary Localized Prostate Cancer: A Voxel-Wise Comparison.

Authors:  Constantinos Zamboglou; Florian Schiller; Tobias Fechter; Gesche Wieser; Cordula Annette Jilg; Alin Chirindel; Nasr Salman; Vanessa Drendel; Martin Werner; Michael Mix; Philipp Tobias Meyer; Anca Ligia Grosu
Journal:  Theranostics       Date:  2016-06-18       Impact factor: 11.556

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.